Higher SARS-COV-2 spike antibody levels are associated with reduced risk of subsequent symptomatic and severe COVID-19. Jin, Yue; Yang, Fei; Rank, Christopher; Letovsky, Stanley; Ramge, Peter and Jochum, Simon from Roche Information Solutions, Roche Diagnostics GmbH, Roche Diagnostics Solutions, and Roche Diagnostics International presented a poster during ISPOR 2024. The objective was to assess the…

Creating a holistic direct to consumer (DTC) and healthcare provider (HCP) marketing strategy from scratch is a demanding task, especially if you don’t have the clinical expertise to precisely identify the consumers or providers you should be targeting. We’re here to give you 5 simple steps to creating a holistic DTC and HCP targeting strategy…

Mapping the patient journey has become more complex, but also more critical to understand what is actually happening in the treatment or therapeutic landscape. This webinar will explore how leveraging PurpleLab’s integrated data sources, including claims and Social Determinants of Health (SDOH), can unlock critical insights for commercial, market access, and medical affairs teams.

Alzheimer’s disease (AD) is a complex and heterogeneous condition requiring early detection and intervention. Biomarkers contribute to diagnostic processes and real-world evidence (RWE) outcomes. Robust real-world data can drive insights to bridge disease, policy, clinical trials, and access gaps in the diagnosis and treatment of AD, providing valuable objective endpoints.

PurpleLab®, a leading health tech company specializing in real-world data and medical claims insights, and Payerset, the industry leader in enterprise price transparency data, announced today a strategic partnership to launch a trusted price intelligence solution suite, setting a new standard in healthcare intelligence.  This collaboration empowers healthcare organizations with unparalleled accuracy and actionable insights,…

Enhance clinical trial development with PurpleLab’s data-driven insights. ​ Access patient-level data, optimize trial design, improve recruitment, and generate real-world evidence.

Launching a new pharmaceutical product is a high-stakes endeavor, with nearly 40% of launches failing to meet expectations. To improve these odds, companies must shift to a data-driven approach, leveraging real-world insights to engage decision-makers effectively across the patient journey.

This case study explores how a pharmaceutical company successfully planned and executed a Phase III clinical trial for a new oncology drug.

Authored by Lauren Kushner, Head of Healthcare at MiQ, and Ted Sweetser, VP of Advertising Partnerships and Strategy at PurpleLab. 2024 was a year of considerable change for the pharmaceutical industry. The biggest trend was undoubtedly the progression of the Inflation Reduction Act’s negotiated drug pricing, which sees CMS negotiating on pricing for a published…

Healthcare advertisers and their marketing partners face challenges that other direct to consumer advertisers may not necessarily be confronted with. Namely, the ever-evolving world of privacy regulation and the requirements enacted by the federal and state governments with the goal of helping preserve patient anonymity.

Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge. In a new webinar, sponsored by PurpleLab, experts explore how PurpleLab’s data solutions can help foster a deeper understanding of physician prescribing behavior.